Functional Technologies Corp.
TSX VENTURE : FEB

Functional Technologies Corp.

May 25, 2010 09:00 ET

Functional Technologies Appoints Richard Sherman to Advisory Board

VANCOUVER, BRITISH COLUMBIA--(Marketwire - May 25, 2010) - Functional Technologies Corp. (TSX VENTURE:FEB), a world leader in yeast research and development, today announced it has appointed Mr. Richard (Dick) Sherman, to its Advisory Board.

Dick Sherman has spent his entire career in the biotech field as both legal counsel and as a principal structuring joint ventures, licensing agreements, and mergers and acquisitions. Currently he is Vice President Business Development, Secretary and General Counsel of Hawaii Biotech, Inc., as well as serving as a consultant to the law firm of Goodsill Anderson Quinn & Stifel, in Honolulu.

"As the company moves forward on commercializing its technology pipeline, a critical component of validating and monetizing these technologies includes developing and executing strategic partnerships," said Howard Louie, Chairman and CEO. "We expect that Dick Sherman's formal addition to the group of advisors will greatly assist in this pursuit, and are very pleased to be welcoming him to the company in this capacity."

Mr. Sherman spent more than a decade earlier in his career as Deputy General Counsel of SmithKline Beckman Corporation (now GlaxoSmithKline), has been a partner in the Philadelphia law firm of Pepper Hamilton LLP, and was founder of QED Technologies, Inc., a life science business-consulting firm purchased in 1999 by The Omnicom Group in New York.

Mr. Sherman is currently a principal in a private SBIC Investment Fund, CIP Capital, L.P. as well as a Venture Partner of SCP Private Equity Partners. He has served on the Board of Directors of CytoMed, Inc., Hawaii Biotech, Inc., IBAH, Inc., Kenna Technologies, Inc., Mera Pharmaceuticals, Inc., and Sparta Pharmaceuticals.

About Functional Technologies Corp.

Functional Technologies develops and commercializes proprietary technologies that enhance the natural properties of yeast and algae – nature's microscopic workhorses. Our scientists apply novel techniques to these micro-celled organisms to resolve significant health and quality problems, and generate new opportunities in the global food, beverage and healthcare industries. Our first commercial products are our Phyterra™ line of proprietary yeast strains, designed to reduce the formation of foul-smelling hydrogen sulphide and the carcinogen urethane in wines and other fermented products. With a head office in Vancouver, Functional Technologies has research and development facilities in Prince Edward Island and a U.S. sales office in Napa Valley, California. For more information go to www.functionaltechcorp.com.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information